Sunhawk Vision Biotech (ROCO:7759) EBIT: NT$-172.21 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7759 Sunhawk Vision Biotech Inc ROCO:7759
12 GF Score
Price NT$31.40
! 1 Warning Sign
View Full Analysis

What is Sunhawk Vision Biotech EBIT?

Sunhawk Vision Biotech ROCO:7759 +0.96% 12 EBIT is NT$-172.21 Mil as of Dec. 2025. GuruFocus rates ROCO:7759 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Sunhawk Vision Biotech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-77.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-172.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunhawk Vision Biotech's annualized ROC % for the quarter that ended in Dec. 2025 was -195.61%. Sunhawk Vision Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -825.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunhawk Vision Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9.50%.

Sunhawk Vision Biotech  (ROCO:7759) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunhawk Vision Biotech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-180.446 * ( 1 - 0% )/( (100.55 + 83.946)/ 2 )
=-180.446/92.248
=-195.61 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=573.035 - 17.261 - ( 455.224 - max(0, 21.057 - 490.756+455.224))
=100.55

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=498.806 - 21.279 - ( 401.021 - max(0, 25.422 - 419.003+401.021))
=83.946

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunhawk Vision Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-154.678/( ( (11.13 + max(17.877, 0)) + (8.463 + max(-3.297, 0)) )/ 2 )
=-154.678/( ( 29.007 + 8.463 )/ 2 )
=-154.678/18.735
=-825.61 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 35.138) - (17.261 + 0 + 0)
=17.877

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 17.982) - (21.279 + 0 + 0)
=-3.297

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunhawk Vision Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-172.207/1813.273
=-9.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunhawk Vision Biotech EBIT Related Terms

Sunhawk Vision Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Sunhawk Vision Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunhawk Vision Biotech EBIT Chart

Sunhawk Vision Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -39.63 -15.18 -97.88 -86.93 -172.21

Sunhawk Vision Biotech Semi-Annual Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only -70.80 -19.60 -67.33 -94.87 -77.34

ROCO:7759 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Sunhawk Vision Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunhawk Vision Biotech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunhawk Vision Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunhawk Vision Biotech's EV-to-EBIT falls into.


ROCO:7759
12GF Score
Sunhawk Vision Biotech Inc ROCO:7759
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunhawk Vision Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-172.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-172.21 Mil mean?
Sunhawk Vision Biotech (ROCO:7759) has a EBIT of NT$-172.21 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunhawk Vision Biotech.
Is Sunhawk Vision Biotech's EBIT too high?
Sunhawk Vision Biotech's current EBIT is NT$-172.21 Mil. Overall, Sunhawk Vision Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sunhawk Vision Biotech's EBIT compare to VRTX and REGN?
Sunhawk Vision Biotech's EBIT of NT$-172.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunhawk Vision Biotech. Sunhawk Vision Biotech's current EBIT is NT$-172.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunhawk Vision Biotech stock overvalued right now?
Sunhawk Vision Biotech (ROCO:7759) has a current EBIT of NT$-172.21 Mil. The current EBIT is NT$-172.21 Mil. Sunhawk Vision Biotech's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sunhawk Vision Biotech (ROCO:7759), the current EBIT is NT$-172.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunhawk Vision Biotech Business Description

Address No. 6 Siwei 3rd Road, 17th Floor, Room A1, Lingya District, Kaohsiung, TWN
Sunhawk Vision Biotech Inc is a biotechnology company. The company is focused on developing new solutions for eye health and vision care. The company specializes in research and development of cutting-edge technologies aimed at treating and preventing ocular diseases. Their product portfolio includes products and services for curing dry eyes, myopia, and corneal erosion.
12GF Score

Get the complete analysis for ROCO:7759

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.40
Price